Boron neutron capture therapy for clear cell sarcoma (CCS): Biodistribution study of p-borono-l-phenylalanine in CCS-bearing animal models

Authors:   T. Andoh,T. Fujimoto,T. Sudo,I. Fujita,M. Imabori,H. Moritake,T. Sugimoto,Y. Sakuma,T. Takeuchi,S. Kawabata,M. Kirihata,T. Akisue,K. Yayama,M. Kurosaka,S. Miyatake,Y. Fukumori,H. Ichikawa,
Journal: Applied Radiation and Isotopes
https://doi.org/10.1016/j.apradiso.2011.02.005
Abstract: Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake l-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a remarkably high accumulation of 10B (45–74ppm) in tumor was obtained even in a CCS-bearing animal with a well-controlled biodistribution followed by intravenous administration of l-BPA-fructose complex (500mg BPA/kg).